Nothing Special   »   [go: up one dir, main page]

DE602006021600D1 - Verfahren zur senkung des blutdrucks - Google Patents

Verfahren zur senkung des blutdrucks

Info

Publication number
DE602006021600D1
DE602006021600D1 DE602006021600T DE602006021600T DE602006021600D1 DE 602006021600 D1 DE602006021600 D1 DE 602006021600D1 DE 602006021600 T DE602006021600 T DE 602006021600T DE 602006021600 T DE602006021600 T DE 602006021600T DE 602006021600 D1 DE602006021600 D1 DE 602006021600D1
Authority
DE
Germany
Prior art keywords
blood pressure
reducing
reducing blood
agents
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006021600T
Other languages
English (en)
Inventor
Parobok Ingrid Langsetmo
Todd W Seeley
Robert C Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrogen Inc
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of DE602006021600D1 publication Critical patent/DE602006021600D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Fuel Cell (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602006021600T 2005-09-29 2006-05-05 Verfahren zur senkung des blutdrucks Active DE602006021600D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72230205P 2005-09-29 2005-09-29
PCT/US2006/017507 WO2007040636A1 (en) 2005-09-29 2006-05-05 Methods for reducing blood pressure

Publications (1)

Publication Number Publication Date
DE602006021600D1 true DE602006021600D1 (de) 2011-06-09

Family

ID=36971225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021600T Active DE602006021600D1 (de) 2005-09-29 2006-05-05 Verfahren zur senkung des blutdrucks

Country Status (11)

Country Link
US (1) US20070072817A1 (de)
EP (1) EP1942985B1 (de)
JP (1) JP2009510056A (de)
CN (1) CN101316626A (de)
AT (1) ATE507243T1 (de)
AU (1) AU2006297839B2 (de)
CA (1) CA2623693A1 (de)
DE (1) DE602006021600D1 (de)
HK (1) HK1121083A1 (de)
IL (1) IL190496A0 (de)
WO (1) WO2007040636A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
EP3081648A1 (de) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
AU2012212110A1 (en) 2011-02-02 2013-08-01 Excaliard Pharmaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
KR20240154702A (ko) 2013-12-18 2024-10-25 더 조지 워싱턴 유니버시티 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합
WO2016007589A1 (en) * 2014-07-08 2016-01-14 La Jolla Pharmaceutical Company Methods for treating hypotension
WO2017120438A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
SU1435151A3 (ru) * 1984-04-10 1988-10-30 Санкио Компани Лимитед (Фирма) Способ получени производных пергидротиазепина или их кислотно-аддитивных фармацевтически приемлемых солей
US5194605A (en) * 1989-12-08 1993-03-16 Merck & Co., Inc. Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US6099869A (en) * 1995-04-18 2000-08-08 Nutrition 21 Calcium taurate and antihypertensive drug for hypertension
US5708029A (en) * 1995-11-13 1998-01-13 Vanmoor; Arthur High blood pressure relief method and compositions
US6287586B1 (en) * 1998-09-18 2001-09-11 The University Of British Columbia Pharmaceutical compositions of vanadium biguanide complexes and their use
PT1263464E (pt) * 2000-03-09 2012-12-17 Genzyme Corp Utilização de anticorpos anti-tgf-beta antagonistas para tratar ou para prevenir a perda da função renal
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
CA2599550A1 (en) * 2005-03-11 2006-09-21 Elixir Pharmaceuticals, Inc. Sirt inhibitors that bind to nad
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism

Also Published As

Publication number Publication date
WO2007040636A1 (en) 2007-04-12
AU2006297839A1 (en) 2007-04-12
ATE507243T1 (de) 2011-05-15
CN101316626A (zh) 2008-12-03
JP2009510056A (ja) 2009-03-12
IL190496A0 (en) 2008-11-03
AU2006297839B2 (en) 2011-04-14
EP1942985A1 (de) 2008-07-16
US20070072817A1 (en) 2007-03-29
HK1121083A1 (en) 2009-04-17
EP1942985B1 (de) 2011-04-27
CA2623693A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
EP2068768A4 (de) Verfahren und system zur verbesserung der diastolischen herzfunktion
EA200701995A1 (ru) Способы уменьшения кальцификации
DE602006021600D1 (de) Verfahren zur senkung des blutdrucks
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
DK2324871T4 (da) Citratantikoaguleringssystem til ekstrakorporale blodbehandlinger
DK3357911T3 (da) Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
ATE470354T1 (de) Systeme und verfahren für die ex-vivo-organpflege
ITMO20040191A1 (it) Macchina e metodo per il trattamento extracorporeo di sangue.
DE502005003383D1 (de) Intrakardiale blutpumpe
WO2007056681A3 (en) Methods for administering hypoglycemic agents
DE602005024846D1 (de) Blutdialysator
DE602005017840D1 (de) Blutdruckmonitor
DE602005026030D1 (de) Blutdruckmessgerät
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
NO20076241L (no) Terapier for vaskulaere sykdommer
SMT201300116B (it) Procedimenti e intermedi per la preparazione di uninibitore macrociclico di proteasi di hcv
WO2007038264A3 (en) Gapr-1 methods
ATE530660T1 (de) Enzymatische herstellung von (meth)acrylsäureestern
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ZA200708576B (en) Blood pressure lowering protein hydrolysates
SG156636A1 (en) Carboxylic acid peri -substituted bicyclics for occlusive artery disease
WO2008070552A3 (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
NO20071606L (no) Bruk av IL-16 ved vaskulaere komplikasjoner
TW200744605A (en) Treatment of peripheral arterial occlusive disease